Voyager Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Thanks very much. Happy to be here moderating a fireside chat with Al Sandrock, CEO of Voyager Therapeutics. Al has a tremendous amount of experience and wealth of knowledge in the neurology space, so I'll try to surprise him with some other questions too. Maybe to start, Al, do you want to just give an update and overview of the Voyager pipeline efforts in the tau space, and then we'll kind of dive deeper into some of the other data from Biogen and other key questions there?
Yeah. We're focused on neurotherapeutics. We were born as a gene therapy in the CNS company. I view ourselves as a multimodality neurotherapeutics company. I'd say that we have a sort of a catalyst-rich period coming up. I'd say it's related to the first one would be the tau antibody that we expect to read out actually this quarter. Then we have FDA clearance to introduce our gene therapy tau knockdown program, and we expect to dose the first patient in the coming months. Neurocrine also has one of our capsids going into Friedreich's ataxia, so two shots on goal to see whether we can validate our newly discovered blood-brain barrier penetrant capsids, and see if we can safely dose patients and get evidence of gene expression.
Yeah, so I think those are. When it comes to the gene therapy, we expect to see acute safety early. Capsid-related safety tends to declare itself early. It'll take probably about a year after we start dosing to see evidence of gene expression in the brain. In the case of our tau knockdown program, if we see tau going down, it must be because our vectorized siRNA is being expressed in cells. Then the third readout would be eventually to see whether or not our knockdown program affects tau PET imaging. There's a lot of data that's not only come out already, but will continue to come out that will help us understand the relationship between tau biomarkers and how much of an effect you need on tau before you get clinically significant effects.
We're starting to see some of that data this year with BIIB080, for example.
Yep. Okay. Maybe let's start with the BIIB080 readout. I mean, we thought it was promising proof of concept, but somewhat confounded by the dose response, that maybe it's not an inverse dose response, but certainly they weren't getting more benefit as they pushed the dose. What do you make of the totality of the data?
Yeah. I think there's several pieces of data that I think we should look at together in addition to BIIB080. So we have BIIB080, an intrathecal ASO knocking down the expression of tau. We have a Novartis intrathecal ASO that also knocks down the expression of tau that read out this year. Then we recently had the Arrowhead shuttled siRNA, where we've seen at least the high-level data in a press release. I think all three are very helpful as we think about the BIIB080 data. So we saw what was, the trial failed on the primary endpoint, which was a dose response statistic based on CDR Sum of Boxes. If anything, yeah, there was a slight downward trend. So that's going to destroy any attempt at seeing a dose response statistic.
Nevertheless, I think overall, as you said, I think it validates tau as a target. On ADAS-Cog, we see an effect size superior to the anti-amyloids. We saw that with MMSE, the mini-mental status as well, superior to the anti-amyloids. On CDR Sum of Boxes, at the lowest dose certainly, you saw in the same range, if you will, an effect size in the mid-20% range, similar to the anti-amyloids. So let's start with the biology. When you look at CSF or fluid-based tau biomarkers, from the lowest dose to the highest dose, there wasn't much change. At the lowest dose, it was a 40% reduction. At the highest dose, it was 50%. So you're at the flat part of the dose response curve in terms of tau knockdown. But I think what happened was that what we saw was a dose-dependent increase in a transient acute confusional state.
I think that, I think, is due to intrathecal ASOs having off-target effects. We've seen that with other intrathecal ASOs, several others. Ionis actually published this year papers on transient neuronal inhibition as well as neuronal activation phenomena that can occur with oligonucleotides regardless of sequence. So it's probably related to having a highly negatively charged oligonucleotide, high extracellular concentrations. Remember, you have to give relatively high doses intrathecally in the lumbar cistern if you want to get enough exposure up in the brain, because there's a pretty steep gradient from the lumbar cistern up to the cortex, and even more reduction as you get into deep cortical structures. So to protect those exposures up there, you got to give excessive amounts down in the lumbar cistern.
I think that what we've had was, you maxed out on tau reduction with the ASO because ASOs, they're okay for knockdown. siRNAs are a little bit better because they're catalytic, but you couldn't do much more than 50% knockdown. But the untoward effects, these transient neurological issues degraded, I think, the primary endpoint, which getting confusional state in a patient with Alzheimer's disease is bound to affect Of course.
endpoints, right? Also, there's this peculiar thing where with tau-related drugs, it seems that you have a bigger effect on cognition than on function.
Yeah. Activities of daily living did not look that great in BIIB080 either.
Maybe that's related to the acute confusional state. What I wonder is it masking a potentially even bigger effect if you could achieve, say, 70% knockdown? You can't do that with an ASO because now you really have problems with higher doses, right?
Right. I wanted to point out the Arrowhead data.
Before we go to Arrowhead, let's go to Novartis. They have an intrathecal ASO, also injected into the lumbar cistern, that was positive in PSP, so much so that they are moving it into phase III. They also report encephalopathy, a transient encephalopathy, which I think is akin to this acute confusional state. So two intrathecal ASOs, and I do not think it is related to tau. I think it is related to these transient neurological effects that we have seen with many others. We even saw with Spinraza in the early days.
Yep. Let me get back then.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
